What CDC’s 2025–2026 Respiratory Virus Guidance Means for Patients and Frontline Physicians

Why the 2025–2026 guidance matters now

Every fall, respiratory viruses return. But for the 2025–2026 season, CDC guidance on influenza, COVID-19, and RSV vaccination reflects several important clarifications that affect everyday practice.

The practical takeaway: most Americans 6 months and older should receive a seasonal flu vaccine and an updated COVID-19 vaccine. RSV prevention now follows more defined pathways—one-time vaccination for eligible older adults and either maternal vaccination during pregnancy or infant monoclonal protection for babies.

For physicians, the emphasis remains steady: protect against severe disease, hospitalizations, and deaths—especially among adults 65 and older, pregnant people, infants, immunocompromised patients, and those with chronic conditions.

Influenza: Who should be vaccinated and when

According to CDC’s 2025–2026 influenza guidance, annual flu vaccination is recommended for everyone 6 months of age and older, with rare exceptions.

Timing: Vaccination is ideally completed in September or October, before influenza activity peaks, but vaccination later in the season still provides benefit if viruses are circulating.

Adults 65 and older: CDC continues to preferentially recommend higher-dose or adjuvanted inactivated influenza vaccines for adults 65+. These formulations are designed to generate a stronger immune response in older adults, whose immune systems may respond less robustly to standard-dose vaccines.

If a higher-dose or adjuvanted product is not available, CDC advises that patients should receive any age-appropriate influenza vaccine rather than delay vaccination.

Egg allergy: As in recent seasons, people with egg allergy can receive any licensed, recommended influenza vaccine appropriate for their age and health status.

COVID-19: Updated seasonal vaccination guidance

CDC’s “Stay Up to Date” COVID-19 vaccine guidance continues to recommend seasonal updated COVID-19 vaccination for everyone 6 months and older.

For most adults, this means one updated dose for the season. However, adults 65 and older and people who are moderately or severely immunocompromised may be eligible for additional doses, depending on time since their last vaccination.

After infection: People who recently had COVID-19 can be vaccinated once they have recovered and met criteria to end isolation. CDC notes that some individuals may consider waiting about three months after infection before receiving an updated dose, since infection provides temporary immune boosting. Timing may vary based on risk factors and local virus activity.

Effectiveness context: As CDC emphasizes, updated COVID-19 vaccines are most reliable at preventing severe disease, hospitalization, and death. Protection against infection tends to be lower and may decline over time, particularly as variants evolve.

Myocarditis history: Individuals with a prior history of myocarditis or pericarditis after mRNA COVID-19 vaccination should consult their clinician before additional doses. Decisions are individualized and guided by current CDC precautions.

RSV: Older adults, pregnancy, and infant protection

RSV prevention has become more structured over the past two seasons, and CDC’s current guidance clarifies roles for older adult vaccination, maternal vaccination, and infant monoclonal protection.

Older adults

CDC recommends a one-time RSV vaccine for:

All adults 75 and older.
Adults 60–74 who have risk factors for severe RSV disease, such as chronic heart or lung disease, diabetes, or immunocompromise.

RSV vaccination is not currently recommended annually for older adults. For most eligible individuals, it is a single dose.

Pregnancy and infants

For infant protection, CDC outlines two main pathways:

Maternal RSV vaccination during 32–36 weeks of pregnancy during RSV season.
Nirsevimab, a long-acting monoclonal antibody, given directly to infants entering their first RSV season.

In most cases, an infant does not need both maternal vaccination and nirsevimab. The American Academy of Pediatrics provides additional pediatric-specific guidance to help clinicians decide which approach is appropriate based on timing and medical risk factors.

What’s meaningfully clarified for 2025–2026

Stronger emphasis on higher-dose or adjuvanted flu vaccines for adults 65+.
Clearer eligibility for additional COVID-19 doses in older and immunocompromised adults.
Refined RSV recommendations specifying one-time vaccination for older adults and defined maternal vs. infant pathways.
Continued support for coadministration of respiratory vaccines.

CDC and ACIP guidance remains subject to update if viral patterns shift during the season.

Coadministration: Can patients get these vaccines together?

Yes. CDC states that influenza, COVID-19, and RSV vaccines may be administered at the same visit, using different injection sites.

Patients may experience typical short-term side effects—arm soreness, fatigue, low-grade fever—but coadministration does not reduce vaccine effectiveness.

For patients concerned about side effects, spacing vaccines by a week or two is acceptable, but not required.

Insurance coverage and cost

Under federal law, most ACIP-recommended vaccines are covered without cost-sharing for people with private insurance.

Medicare:

Influenza and COVID-19 vaccines are covered under Medicare Part B.
RSV vaccines for eligible adults are covered under Medicare Part D.

CMS confirms that ACIP-recommended adult vaccines are covered without cost-sharing under Part D.

Medicaid: State Medicaid programs are required to cover ACIP-recommended vaccines for most adult beneficiaries without cost-sharing.

Patients should verify network participation and pharmacy coverage details, particularly for Part D plans.

Common questions physicians are hearing

“Do I need RSV again if I got it last year?”
In most cases, no. RSV vaccination for older adults is currently a one-time dose.

“Can I get flu, COVID, and RSV together?”
Yes. Coadministration is allowed and practical for many patients.

“If I already had COVID this year, should I still get vaccinated?”
Yes. Vaccination restores and broadens protection, especially against severe disease. Timing may be individualized.

“Is protection guaranteed?”
No vaccine prevents all infections. The primary goal is reducing severe illness, hospitalization, and death.

What this means for patients and clinicians

For the 2025–2026 season, the strategy is layered but straightforward:

Most people 6 months and older: flu and updated COVID-19 vaccination.
Adults 65+: preferential high-dose/adjuvanted flu vaccine and attention to COVID-19 booster eligibility.
Eligible older adults: one-time RSV vaccination.
Pregnant people: maternal RSV vaccine during the recommended window.
Infants: nirsevimab when maternal vaccination was not given or timing requires it.

Respiratory virus guidance evolves as data change. For now, CDC’s recommendations prioritize preventing severe disease and protecting the people most likely to experience complications.

For frontline physicians, the message remains consistent: vaccinate early, use coadministration when appropriate, clarify coverage, and focus conversations on protecting against hospitalization and death—not just infection.

Sources

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.